In a study reported yesterday in JAMA Internal Medicine, children and adolescents previously diagnosed with multisystem inflammatory syndrome (MIS-C) reported no serious complications after COVID-19 vaccination. Almost all participants received the Pfizer COVID-19 vaccine. The Centers for Disease Control and Prevention recommends COVID-19 vaccination for patients with a history of MIS-C, a rare and potentially fatal immune reaction to SARS-CoV-2 infection. According to CDC data, over 9,000 U.S. patients have been diagnosed with MIS-C, which appears to be on the decline.
 
“A big part of that decline is that COVID vaccination has been protective against this rare condition in those who have received it,” said Audrey Dionne, M.D., a pediatric cardiologist at Boston Children’s Hospital who served as co-leader for the study, funded by the National Institutes of Health.

Related News Articles

Headline
An infographic released by the University of Minnesota Rural Health Research Center highlights the decline of maternity care access in rural counties across…
Headline
The Health Resources and Services Administration June 11 announced that Montana is eligible for $5.4 million in federal funding this year for the Maternal,…
Headline
The award-winning Beyond Birth podcast series helps bring hospital programs to life by telling personal stories of how they positively impact mothers and their…
Blog
Our health may be the most personal and important thing we have. It determines how we feel when we wake up in the morning, how we relate to our families and…
Blog
The RAND Corporation recently released the fifth iteration of its biannual hospital price report. The AHA has previously highlighted significant flaws with…
Headline
Health care organizations can create more inclusive, responsive and effective maternal health initiatives that address the unique challenges Black women…